Gastrin compositions and formulations, and methods of use and preparation
AssigneeWarath Pharmaceuticals, Inc
InventorAntonio Cruz
Life of this patent
Estimating the term…
Abstract
The present invention concerns six novel variants of alternative splicing of the CD40 receptor The invention provides a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin/CCK receptor, to various carrier moieties, including the use of amino acid spacer regions, and use of bifunctional cross-linking reagents. Methods of treating a diabetes patient with the compositions are provided.
Claims15
A gastrin compound which comprises an amino acid sequence comprising from the amino acid terminus Z—Ym—Xn-AA1-AA2-AA3-AA4-AA5-AA6, wherein Z is human serum albumin;
- Xn is Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala (SEQ ID NO:9). AA1-AA2-AA3-AA4-AA5-AA6 is Tyr-Gly-Trp-Leu-Asp-Phe (SEQ ID NO:6) or Tyr-Gly-Trp-Met-Asp-Phe (SEQ ID NO:5), Ym is an optional spacer region comprising m amino acid residues of a small neutral amino acid, and wherein there is a cysteine residue at the amino terminus of Y wherein m is 1 or greater, or at the amino terminus of X when m is 0, providing that the gastrin compound binds a gastrin/CCKB receptor.
A pharmaceutical composition comprising the gastrin compound of wherein said gastrin has extended activity upon administration to a subject in comparison with native gastrin.
A pharmaceutical composition comprising the gastrin compound of wherein said gastrin prevents severe hypoglycemia or increases pancreatic insulin content upon administration to a subject.
Dependencies are inferred from the claim text.